Juan Shan1, Li Feng2, Guixiang Sun2, Peng Chen2, Yanni Zhou2, Mengjuan Xia2, Hongsheng Li2, Youping Li3. 1. Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, PR China; Regenerative Medicine Research Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, PR China. 2. Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, PR China. 3. Key Laboratory of Transplant Engineering and Immunology of Health Ministry of China, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, PR China; Chinese Cochrane Centre, Chinese Evidence-Based Medicine Centre, Chengdu 610041, Sichuan Province, PR China. Electronic address: yzmylab@hotmail.com.
Abstract
BACKGROUND: Immune response outcome, inflammation or tolerance, often depends on the balance between regulatory T cells (Tregs) and effective T cells (Teffs). Rapamycin (Rapa) has been reported to selectively expand Tregs and promote de novo generation of foxp3(+) Tregs, suggesting its potential role in inducing tolerance. But the mechanism by which Rapa regulating the Treg-Teff balance is yet to be understood. METHODS: Mouse CD4(+)CD25(-) Teffs and CD4(+)CD25(+) Tregs are sorted by MACS. These T cell subsets were labeled with CFSE and cultured with anti-CD3/CD28 Ab±IL-2 for 6 days. Two rounds of stimulation of 3 days each were performed. Rapa or Jak Inhibitor I was added to the culture when indicated. Cells were harvested after each round of stimulation. CFSE dilution, FOXP3, miR-155 expression and the signaling via the mTOR and STAT5 pathways were determined. And miR-155-mimic and miR-155-antagomir were transfected into purified CD4(+) T cells respectively to detect miR-155 role in regulating STAT5 signaling. RESULTS: Firstly, we confirmed that the effect of Rapa on proliferating T cells is time-dependent: it reduces both Teffs and Tregs proliferation at early stage, but selectively promotes Tregs proliferation after second round of stimulation. Then we found there is direct interaction between mTOR and STAT5 signaling, and this interaction explained the time-dependent effect of Rapa and may participate in deciding Teff-Treg balance: mTOR inhibition up-regulated the expression of phos-STAT5 in both proliferating Tregs and Teffs via miR-155. And foxp3 is the down streaming target of phos-STAT5, thus Rapa could maintain expanded Tregs function and promote de novo generation of foxp3(+) Tregs. However, the phos-4E-BP1 expression pattern is different in proliferating Tregs and Teffs. 4E-BP1 is the common target of mTOR and STAT5 signaling, and plays a key role in cell proliferation. Rapa inhibits phos-4E-BP1 expression in both Tregs and Teffs at early stage of proliferation, but selectively raises its expression in Tregs after second round of stimulation. This may explains why Rapa inhibits Teffs growth, but delays Tregs proliferation. CONCLUSION: Together, these findings indicate that the dynamic interaction between mTOR and STAT5 signaling modulates the reciprocal differentiation of the effective and regulatory T cells, and differently affect their proliferation activity. This provides a new insight of how Treg-Teff balance is regulated.
BACKGROUND: Immune response outcome, inflammation or tolerance, often depends on the balance between regulatory T cells (Tregs) and effective T cells (Teffs). Rapamycin (Rapa) has been reported to selectively expand Tregs and promote de novo generation of foxp3(+) Tregs, suggesting its potential role in inducing tolerance. But the mechanism by which Rapa regulating the Treg-Teff balance is yet to be understood. METHODS:Mouse CD4(+)CD25(-) Teffs and CD4(+)CD25(+) Tregs are sorted by MACS. These T cell subsets were labeled with CFSE and cultured with anti-CD3/CD28 Ab±IL-2 for 6 days. Two rounds of stimulation of 3 days each were performed. Rapa or Jak Inhibitor I was added to the culture when indicated. Cells were harvested after each round of stimulation. CFSE dilution, FOXP3, miR-155 expression and the signaling via the mTOR and STAT5 pathways were determined. And miR-155-mimic and miR-155-antagomir were transfected into purified CD4(+) T cells respectively to detect miR-155 role in regulating STAT5 signaling. RESULTS: Firstly, we confirmed that the effect of Rapa on proliferating T cells is time-dependent: it reduces both Teffs and Tregs proliferation at early stage, but selectively promotes Tregs proliferation after second round of stimulation. Then we found there is direct interaction between mTOR and STAT5 signaling, and this interaction explained the time-dependent effect of Rapa and may participate in deciding Teff-Treg balance: mTOR inhibition up-regulated the expression of phos-STAT5 in both proliferating Tregs and Teffs via miR-155. And foxp3 is the down streaming target of phos-STAT5, thus Rapa could maintain expanded Tregs function and promote de novo generation of foxp3(+) Tregs. However, the phos-4E-BP1 expression pattern is different in proliferating Tregs and Teffs. 4E-BP1 is the common target of mTOR and STAT5 signaling, and plays a key role in cell proliferation. Rapa inhibits phos-4E-BP1 expression in both Tregs and Teffs at early stage of proliferation, but selectively raises its expression in Tregs after second round of stimulation. This may explains why Rapa inhibits Teffs growth, but delays Tregs proliferation. CONCLUSION: Together, these findings indicate that the dynamic interaction between mTOR and STAT5 signaling modulates the reciprocal differentiation of the effective and regulatory T cells, and differently affect their proliferation activity. This provides a new insight of how Treg-Teff balance is regulated.
Authors: Francisco Boix-Giner; Olga Millan; David San Segundo; Pedro Muñoz-Cacho; Esther Mancebo; Santiago Llorente; Lourdes Rafael-Valdivia; Antoni Rimola; Emilio Fábrega; Anna Mrowiec; Luis Allende; Alfredo Minguela; Jose M Bolarín; Estela Paz-Artal; Marcos López-Hoyos; Mercé Brunet; Manuel Muro Journal: Int Immunol Date: 2015-08-12 Impact factor: 4.823
Authors: Hsin-Yuan Cheng; Dalia E Gaddis; Runpei Wu; Chantel McSkimming; LaTeira D Haynes; Angela M Taylor; Coleen A McNamara; Mary Sorci-Thomas; Catherine C Hedrick Journal: J Clin Invest Date: 2016-08-02 Impact factor: 14.808